JY
ALLO icon

Jeff Yass’s Allogene Therapeutics ALLO Stock Holding History

Jeff Yass’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Sell
93,641
-33,119
-26% -$72.7K ﹤0.01% 11981
2026
Q1 		$309K Buy
126,760
+35,507
+39% +$71.2K ﹤0.01% 10791
2025
Q4 		$125K Buy
91,253
+22,753
+33% +$30K ﹤0.01% 11318
2025
Q3 		$84.9K Sell
68,500
-236,312
-78% -$282K ﹤0.01% 11655
2025
Q2 		$344K Buy
304,812
+147,168
+93% +$196K ﹤0.01% 10031
2025
Q1 		$230K Buy
157,644
+4,042
+3% +$7.62K ﹤0.01% 10640
2024
Q4 		$327K Buy
153,602
+71,146
+86% +$175K ﹤0.01% 9634
2024
Q3 		$231K Sell
82,456
-5,286
-6% -$14.1K ﹤0.01% 10168
2024
Q2 		$204K Sell
87,742
-8,064
-8% -$23.8K ﹤0.01% 10312
2024
Q1 		$428K Sell
95,806
-153,505
-62% -$641K ﹤0.01% 8880
2023
Q4 		$800K Sell
249,311
-77,055
-24% -$219K ﹤0.01% 7540
2023
Q3 		$1.03M Sell
326,366
-11,610
-3% -$50.9K ﹤0.01% 6559
2023
Q2 		$1.68M Sell
337,976
-161,958
-32% -$876K ﹤0.01% 5515
2023
Q1 		$2.47M Buy
499,934
+434,954
+669% +$2.79M ﹤0.01% 4712
2022
Q4 		$409K Sell
64,980
-138,239
-68% -$1.28M ﹤0.01% 8347
2022
Q3 		$2.19M Buy
203,219
+41,307
+26% +$561K ﹤0.01% 4724
2022
Q2 		$1.85M Sell
161,912
-17,108
-10% -$152K ﹤0.01% 5085
2022
Q1 		$1.63M Sell
179,020
-65,309
-27% -$680K ﹤0.01% 5937
2021
Q4 		$3.65M Buy
244,329
+142,706
+140% +$2.52M ﹤0.01% 4303
2021
Q3 		$2.61M Buy
101,623
+15,997
+19% +$380K ﹤0.01% 5255
2021
Q2 		$2.23M Sell
85,626
-68,624
-44% -$1.96M ﹤0.01% 5665
2021
Q1 		$5.45M Buy
154,250
+92,410
+149% +$3.12M ﹤0.01% 3739
2020
Q4 		$1.56M Buy
61,840
+40,388
+188% +$1.32M ﹤0.01% 5650
2020
Q3 		$809K Sell
21,452
-2,761
-11% -$104K ﹤0.01% 6641
2020
Q2 		$1.04M Sell
24,213
-23,710
-49% -$857K ﹤0.01% 5839
2020
Q1 		$932K Buy
+47,923
New +$1.14M ﹤0.01% 5573
2019
Q4 		– Sell
-30,447
Closed -$839K – 9639
2019
Q3 		$830K Sell
30,447
-11,234
-27% -$320K ﹤0.01% 6109
2019
Q2 		$1.12M Buy
+41,681
New +$1.16M ﹤0.01% 5395

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's ALLO Position: Q2 2026 in Review

Jeff Yass reduced its Allogene Therapeutics (ALLO) stake by 26% in Q2 2026, selling an estimated $72.7K and leaving 93,641 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #11981.

Jeff Yass first reported a position in ALLO in Q2 2019 and has held it in 28 quarters since. The position peaked at $5.45M in Q1 2021. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Jeff Yass held 93,641 shares of Allogene Therapeutics worth $195K as of Q2 2026.
  • Jeff Yass sold 33,119 Allogene Therapeutics shares in Q2 2026, an estimated $72.7K.
  • Allogene Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11981 holding.
  • Jeff Yass first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Jeff Yass's Allogene Therapeutics position peaked at $5.45M in Q1 2021.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.